Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCABNASDAQ:GRCLNASDAQ:ITOSNASDAQ:SBTXNYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$0.38+1.3%$0.43$0.24▼$2.53$22.26M0.91914,684 shs432,781 shsGRCLGracell Biotechnologies$10.25$10.25$1.40▼$10.44$744.95M-0.331.32 million shsN/AITOSiTeos Therapeutics$10.10-0.8%$8.98$4.80▼$18.13$387.10M1.49690,934 shs270,389 shsSBTXSilverback Therapeutics$16.52-1.4%$14.79$2.80▼$8.97$595.68M0.6337,931 shs881,491 shsVORVor Biopharma$2.86+49.6%$0.45$0.13▼$2.96$361.01M2.044.39 million shs38.11 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla0.00%-1.04%-21.15%+30.99%-71.21%GRCLGracell Biotechnologies0.00%0.00%0.00%0.00%0.00%ITOSiTeos Therapeutics0.00%+2.21%0.00%+93.71%-27.43%SBTXSilverback Therapeutics0.00%-9.23%+22.92%+29.06%+81.54%VORVor Biopharma0.00%+77.83%+742.27%+246.70%+107.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCABBioAtla2.7275 of 5 stars3.32.00.00.03.12.50.6GRCLGracell BiotechnologiesN/AN/AN/AN/AN/AN/AN/AN/AITOSiTeos Therapeutics3.1841 of 5 stars4.12.00.00.01.43.30.6SBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVORVor Biopharma3.9713 of 5 stars4.35.00.00.02.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCABBioAtla 2.50Moderate Buy$5.001,212.34% UpsideGRCLGracell Biotechnologies 0.00N/AN/AN/AITOSiTeos Therapeutics 2.14Hold$15.8657.08% UpsideSBTXSilverback Therapeutics 0.00N/AN/AN/AVORVor Biopharma 2.60Moderate Buy$5.6397.01% UpsideCurrent Analyst Ratings BreakdownLatest SBTX, BCAB, GRCL, ITOS, and VOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$3.006/26/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Outperform5/28/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$13.00 ➝ $12.005/28/2025ITOSiTeos TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$10.00 ➝ $12.005/14/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$16.00 ➝ $13.005/14/2025ITOSiTeos TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$12.005/14/2025ITOSiTeos TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$16.00 ➝ $12.005/14/2025ITOSiTeos TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/14/2025ITOSiTeos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/14/2025ITOSiTeos TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$47.00 ➝ $9.005/13/2025ITOSiTeos TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$15.00 ➝ $8.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCABBioAtla$11M2.02N/AN/A$0.25 per share1.52GRCLGracell Biotechnologies$60K12,415.83N/AN/A$2.95 per share3.47ITOSiTeos Therapeutics$35M11.04N/AN/A$16.16 per share0.62SBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/AVORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCABBioAtla-$69.78M-$1.22N/AN/AN/AN/A-373.47%-116.55%8/6/2025 (Estimated)GRCLGracell Biotechnologies-$88.08M-$1.05N/AN/AN/AN/A-37.40%-31.24%N/AITOSiTeos Therapeutics-$134.41M-$3.04N/AN/AN/AN/A-21.37%-18.55%8/6/2025 (Estimated)SBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/AVORVor BiopharmaN/A-$1.51N/AN/AN/AN/AN/AN/AN/ALatest SBTX, BCAB, GRCL, ITOS, and VOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025BCABBioAtla-$0.28-$0.29-$0.01-$0.26N/AN/A4/28/2025Q1 2025ITOSiTeos Therapeutics-$0.94-$0.80+$0.14-$0.80$9.35 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCABBioAtlaN/AN/AN/AN/AN/AGRCLGracell BiotechnologiesN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCABBioAtlaN/A2.352.35GRCLGracell Biotechnologies0.027.737.73ITOSiTeos TherapeuticsN/A14.1314.13SBTXSilverback TherapeuticsN/A67.8767.87VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCABBioAtla77.23%GRCLGracell BiotechnologiesN/AITOSiTeos Therapeutics97.16%SBTXSilverback Therapeutics74.89%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipBCABBioAtla11.50%GRCLGracell Biotechnologies28.00%ITOSiTeos Therapeutics12.50%SBTXSilverback Therapeutics34.40%VORVor Biopharma2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCABBioAtla6058.42 million51.70 millionOptionableGRCLGracell Biotechnologies31472.68 million52.33 millionOptionableITOSiTeos Therapeutics9038.27 million33.49 millionOptionableSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableVORVor Biopharma140124.96 million65.45 millionNot OptionableSBTX, BCAB, GRCL, ITOS, and VOR HeadlinesRecent News About These CompaniesBoston’s biotech sector reels due to Trump health policy uncertaintyJuly 6 at 3:56 PM | ft.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 5 at 2:37 AM | marketbeat.comHC Wainwright Predicts Weaker Earnings for Vor BiopharmaJuly 4 at 2:35 AM | americanbankingnews.comVor Biopharma Q2 EPS Estimate Decreased by HC WainwrightJuly 2, 2025 | marketbeat.comHC Wainwright Upgrades Vor Biopharma (NYSE:VOR) to "Buy"July 2, 2025 | americanbankingnews.comVor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 1, 2025 | globenewswire.comHC Wainwright & Co. Upgrades Vor Biopharma (VOR)June 30, 2025 | msn.comVor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune MarketJune 30, 2025 | benzinga.comVor Bio Stock Skyrockets 250% in the Past Week: Here's WhyJune 30, 2025 | zacks.comVor Biopharma (NYSE:VOR) Upgraded at HC WainwrightJune 30, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Gains Momentum S&P 500June 27, 2025 | kalkinemedia.comKVor Biopharma Inc. Stock Grades - Barron'sJune 27, 2025 | barrons.comVor Biopharma (NYSE:VOR) Stock Price Expected to Rise, Robert W. Baird Analyst SaysJune 27, 2025 | marketbeat.comVor, with new CEO, changes course to target autoimmune diseaseJune 26, 2025 | biopharmadive.comBAfter axing 95% workforce, Vor bets $4B+ on Remegen’s telitaciceptJune 26, 2025 | bioworld.comBVor Biopharma Insider Trading Activity | NASDAQ:VOR | BenzingaJune 26, 2025 | benzinga.comVor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactionsJune 26, 2025 | fiercepharma.comFVor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune TherapyJune 26, 2025 | msn.comVor Biopharma Target of Unusually High Options Trading (NYSE:VOR)June 26, 2025 | marketbeat.comVor Biopharma: Vor Bio Announces $175 Million Private PlacementJune 26, 2025 | finanznachrichten.deVor Biopharma: Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune AssetJune 26, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSBTX, BCAB, GRCL, ITOS, and VOR Company DescriptionsBioAtla NASDAQ:BCAB$0.38 +0.00 (+1.30%) As of 03:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Gracell Biotechnologies NASDAQ:GRCLGracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.iTeos Therapeutics NASDAQ:ITOS$10.10 -0.08 (-0.74%) As of 03:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.Silverback Therapeutics NASDAQ:SBTX$16.52 -0.23 (-1.37%) As of 07/3/2025Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Vor Biopharma NYSE:VOR$2.86 +0.95 (+49.74%) As of 03:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Warehouse Wars: Can BJ’s Take Advantage of Costco’s Weakness? Why Freeport-McMoRan Is The Copper King in a Tight Market Correction Equals Opportunity in Domino’s Pizza Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.